Decoy Therapeutics Inc. (DCOY) Ownership
DCOY ownership summary
as of October 18, 2026- Institutions
- 2.7% of shares outstanding
- Insiders
- 2.87% of shares outstanding
- Shares outstanding
- 2.4M
- Float
- 586K shares available to trade
- Short interest
- 23.05% 150K shares short
- Days to cover
- 0.02 short interest up 1,321.2% vs prior month
- Institutions 2.66%
- Insiders 2.87%
- Other investors 94.48%
DCOY top institutional holders
12 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management, LLC | 0.76% | 4,034 | $4,720 | +4,034 (0.0%) | June 30, 2026 |
| 2 | Tower Research Capital LLC | 0.05% | 256 | $300 | −765 (−74.9%) | June 30, 2026 |
| 3 | UBS Group AG | <0.01% | 25 | $29 | −521 (−95.4%) | June 30, 2026 |
| 4 | Caitong International Asset Management Co., Limited. | <0.01% | 2 | $2 | +2 (0.0%) | June 30, 2026 |
| 5 | Danske Bank A/S. | 0.00% | — | — | −2 (−100.0%) | March 31, 2026 |
| 6 | Morgan Stanley - Brokerage Accounts | 0.00% | — | — | −1 (−100.0%) | June 30, 2026 |
| 7 | Advisory Services Network, LLC | 0.00% | — | — | −41 (−100.0%) | June 30, 2026 |
| 8 | Warberg Asset Management LLC | 0.00% | — | — | −28,000 (−100.0%) | March 31, 2026 |
| 9 | Geode Capital Management, LLC | 0.00% | — | — | −10,922 (−100.0%) | March 31, 2026 |
| 10 | Advisor Group Holdings, Inc. | 0.00% | — | — | −3 (−100.0%) | March 31, 2026 |
| 11 | XTX Topco Ltd | 0.00% | — | — | −10,941 (−100.0%) | March 31, 2026 |
| 12 | Bank of America Corp | 0.00% | — | — | −36 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 12, 2 holders added 4,036 shares and 10 cut 51K.
DCOY top mutual fund and ETF holders
3 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 1.43% | 7,614 | $8,908 | +4,710 (+162.2%) | August 31, 2026 |
| 2 | Fidelity Series Total Market Index | 0.09% | 477 | $558 | — | August 31, 2026 |
| 3 | Horizon Kinetics Medical ETF | <0.01% | 20 | $23 | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
DCOY shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns DCOY
Institutional investors own 2.7% of Decoy Therapeutics's shares and insiders 2.87%. The largest holder is Vanguard Capital Management, LLC with 0.76% of the shares (4,034), as of June 30, 2026. Among the top 12 institutions, 2 added shares and 10 reduced their stake in the latest filings. Short interest is 23.05% of the float, or 0.02 days of average trading volume. The share count rose 26,655.6% since 2014.
Related: DCOY analyst forecast, DCOY key metrics. See the DCOY stock overview for the latest quote and news.
DCOY ownership FAQ
Who owns the most Decoy Therapeutics stock?
The largest shareholders of Decoy Therapeutics are Vanguard Capital Management, LLC (0.76%), Tower Research Capital LLC (0.05%), UBS Group AG (<0.01%), Caitong International Asset Management Co., Limited. (<0.01%), Danske Bank A/S. (0.00%).
What percentage of Decoy Therapeutics is owned by institutions?
Institutions hold 2.7% of Decoy Therapeutics's shares outstanding; insiders hold 2.87%.
Which funds own Decoy Therapeutics?
The largest fund holders of Decoy Therapeutics are Fidelity Extended Market Index (1.43%), Fidelity Series Total Market Index (0.09%), Horizon Kinetics Medical ETF (<0.01%).
What is Decoy Therapeutics's short interest?
150K shares of Decoy Therapeutics were sold short, 23.05% of the float; at the average daily volume it would take 0.02 days to cover.
How many shares of Decoy Therapeutics are outstanding?
Decoy Therapeutics has 2.4M shares outstanding, of which 586K are in the public float.